Anhui Biochem Pharmaceutical (Africa) (IFC-606205)

Regions
  • Africa
Geographic location where the impacts of the investment may be experienced.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Active
Stage of the project cycle. Stages vary by development bank and can include: pending, approval, implementation, and closed or completed.
Bank Risk Rating
U
Environmental and social categorization assessed by the development bank as a measure of the planned project’s environmental and social impacts. A higher risk rating may require more due diligence to limit or avoid harm to people and the environment. For example, "A" or "B" are risk categories where "A" represents the highest amount of risk. Results will include projects that specifically recorded a rating, all other projects are marked ‘U’ for "Undisclosed."
Borrower
Anhui Biochem United Pharmaceutical Co.
A public entity (government or state-owned) provided with funds or financial support to manage and/or implement a project.
Sectors
  • Education and Health
  • Finance
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
Advisory Services
The categories of the bank investment: loan, grant, guarantee, technical assistance, advisory services, equity and fund.
Project Cost (USD)
$ 0.15 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Primary Source

Original disclosure @ IFC website

Updated in EWS Apr 4, 2024

Disclosed by Bank Aug 10, 2021

Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description
If provided by the financial institution, the Early Warning System Team writes a short summary describing the purported development objective of the project and project components. Review the complete project documentation for a detailed description.

This Upstream Project entails an opportunity for IFC to support Anhui Biochem United Pharmaceutical Co., Ltd. (“Anhui Biochem”) to identify and develop opportunities for the local production for HIV/AIDS and Hepatitis B drugs in selected African countries through the creation of local manufacturing partnerships. Anhui Biochem is one of China's leading biotech companies engaged in the development, manufacturing and supply of antiretroviral drugs, currently exporting its products to 33 countries. Increasing local pharmaceutical production will potentially ease the current strain on African government budgets and foreign exchange demands arising from a high reliance on imported products critical for the treatment of killer diseases such as HIV/AIDS and Hepatitis B. In addition, on-continent production will reduce the vulnerability of African populations to the type of supply-chain disruptions encountered as a result of the COVID-19 pandemic.

The Project requires Upstream support to identify the markets with: (i) the strongest manufacturing capabilities, (ii) a well-suited enabling environment, (iii) appropriate potential local partners, (iv) an evaluation of the technological and economic feasibility of each opportunity backed by well-structured economic and financial analyses, and (v) a compilation of the project roadmap to investment. IFC intends to provide advisory services to facilitate partner engagements, as well as co-funding and relevant internal expertise to manage external consulting engagements and studies required to reach investment readiness within the next three years.

People Affected By This Project
People Affected By This Project refers to the communities of people likely to be affected positively or negatively by a project.

The project seeks to build and strengthen local pharmaceutical and medical manufacturing capabilities. In turn, the project will result in (i) increasing availability of critical pharmaceutical products in Africa and (ii) diversifying the pharmaceutical value chain and increasing local manufacturing capacities for critical pharmaceutical products. Overall, this increases resilience of the country and the region, especially during times of supply chain disruptions as demonstrated by COVID-19.

Investment Description
Here you can find a list of individual development financial institutions that finance the project.
Private Actor 1 Private Actor 1 Role Private Actor 1 Sector Relation Private Actor 2 Private Actor 2 Role Private Actor 2 Sector
- - - - Anhui Biochem United Pharmaceutical Co. Client -

Contact Information
This section aims to support the local communities and local CSO to get to know which stakeholders are involved in a project with their roles and responsibilities. If available, there may be a complaint office for the respective bank which operates independently to receive and determine violations in policy and practice. Independent Accountability Mechanisms receive and respond to complaints. Most Independent Accountability Mechanisms offer two functions for addressing complaints: dispute resolution and compliance review.

 

“No contacts available at the time of disclosure.”

 


ACCESS TO INFORMATION

You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org

How it works

How it works